Saleha Patel
Pipeline & Commercialisation Strategy Head Constructive Bio
Seminars
Thursday 16th April 2026
Panel Discussion: Collating the Lessons Learned from FDA Approved Drugs to Inform the Future of GLP-1 Based Therapies & Ensure a Next- Generation of More Patient Centered Approaches
4:00 pm
- Broadening the therapeutic scope of GLP-1s as the new frontier for a wide range of new applications, such as cardiovascular disease, neurodegenerative disorders and ageing, offering patients a more comprehensive approach to health beyond just weight loss
- Enhancing drug delivery for patient success to improve patient adherence through less frequent administration, including once-a-month injections and oral medications, providing a convenient and less intrusive treatment experience that supports longterm adherence
- Integrating a complementary ecosystem of care for collaborative approach of chronic drugs, advanced combinations, and procedural solutions that work together to create a personalized treatment plan for each patient, maximizing chances of achieving sustainable metabolic health
Wednesday 15th April 2026
Advancing Next-Generation Therapeutics with Programmable Biology: Disrupting the GLP-1 Paradigm for Enhanced Treatment Diversity at Scale
1:30 pm
- Utilizing genetic code expansion and engineered translation for the incorporation of non-canonical amino acids (ncAAs) for creating new-to-nature biotherapeutics; enabling drug candidates with improved stability, efficacy, and novel mechanisms of action beyond traditional incretin agonism
- Exploring how sustainable biomanufacturing is strategically important to overcome the high cost and inefficiency of existing chemical peptide synthesis methods, ensuring that next-generation peptide therapeutics can meet massive global demand at partner-grade quality and industry-scale titres
- Prioritizing platform technologies in commercialization strategies that enable rapid, cost-effective scale-up and yield differentiated value, moving the field past dose-optimization of existing drugs toward wholly novel, patient-focused treatments
